Home・Elenco Azioni・Insmed

Insmed

Chiusa

SettoreSettore sanitario

98.72 0.46

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

96.22

Massimo

99.38

Metriche Chiave
By Trading Economics
Entrata	165M -164M
Vendite	42M 306M
EPS	-0.76
Margine di Profitto	-53.458
Dipendenti	1,664
EBITDA	164M -136M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+100.98% upside

Dividendi
By Acuity
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-7.5B 23B
Apertura precedente	98.26
Chiusura precedente	98.72

Notizie sul Sentiment di mercato

By Acuity

43%

57%

135 / 340 Classifica in Healthcare

Insmed Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 lug 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 lug 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 lug 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 lug 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 lug 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 lug 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 lug 2026, 17:41 UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 lug 2026, 19:16 UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Confronto tra pari

Modifica del prezzo

Insmed Previsione

Obiettivo di Prezzo

By TipRanks

100.98% in crescita

Previsioni per 12 mesi

Media 198.17 USD 100.98%

Alto 243 USD

Basso 160 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Insmed - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Insmed - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

135 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.